cyrilzakka/clinical-trials huggingface dataset:
Pedometers and Walking Tests for Pulmonary Hypertension Patients

Concordance between walking tests and pedometer data may seem like a logical outcome for pulmonary hypertension (PH) patients. However, many individuals have discordant results: results much worse or better during an in-hospital walking test as compared to real life activity.

The primary objective of this study is: to determine variables associated with discordance between the distance walked during an in-hospital 6-minute walking test (6MWT) and the average distance travelled per day (observed over a period of 28 days (2 × 14 days) using a pedometer) among PH patients.

Secondarily, the discordance between 6MWT results versus total pedometer recorded distance and versus maximum daily pedometer-recorded distance will be similarly studied. The aim of the study is also to search for variables associated with progression free survival. The relationships between pedometer data and self-reported dyspnea variation will be studied. Factorial analysis may be used to study the overall view of variable correlations and patient similarity/dissimilarity.

Eligibility Criteria:
Inclusion Criteria:

* Patient with idiopathic pulmonary hypertension (PH), familial PH, or PH associated with various pathologies (groups I to IV of the international classification)
* New York Heart Association (NYHA) severity classes II to IV
* Incident cases, or prevalent cases with stable disease over the last 3 months
* Collection of informed written consent
* Affiliation with or beneficiary of a social security program (health insurance)
* Outpatient consulting at the hospital on the day of inclusion
* 6 minute walking test on day of inclusion

Exclusion Criteria:

* Patients protected or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP)
* Pregnant or lactating women according to article L1121-5 of the CSP
* Vulnerable persons according to article L1121-6 of the CSP
* Simultaneous participation in any other research protocol
* It is impossible to correctly inform the patient (language barrier, etc.)
* The patient has already been included in the study
3D MR Versus 3D CT for Glenohumeral Arthritis

This study aims to assess the efficacy of three-dimensional magnetic resonance (MR) compared to three-dimensional computed tomography (CT) imaging. This proposed study is a prospective, unrandomized, single-blinded, self-controlled, and single-armed diagnostic radiological evaluation study.


Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from glenohumeral OA;
* Radiographic evidence of severe glenoid erosion;
* Indication for TSA based on clinical exam;
* Patient is willing to participate by complying with pre-operative visit requirements;
* Patient is willing and able to review and sign a study informed consent form.

Exclusion Criteria:

* Prior arthroplasty at the affected shoulder;
* Patients with inflammatory arthritis;
* Patients with post-capsulorrhaphy arthritis;
* Patients with post-traumatic arthritis;
* Patients with rotator cuff tear arthropathy;
* Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedures;
* Patients who are pregnant;
* Patients with implanted medical devices that are contraindicated to exposure up to a 3.0-tesla magnetic field.
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.

42 patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.

All the patients will continue herpesvirus prophylaxis with acyclovir or valacyclovir.

Patients will be evaluated biweekly until letermovir discontinuation. A PCR CMV test will be performed biweekly. Patients in whom clinically significant CMV infection (defined as CMV disease or CMV viremia leading to preemptive treatment) develop, will discontinue the trial regimen and begin anti-CMV therapy according to local practice. The threshold for preemptive treatment for CMV viremia will be \>1000 copies/ ml.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients
* After allogeneic transplantation
* Seropositive for CMV
* Who already received letermovir prophylaxis until day 100 without CMV reactivation
* Beyond day 100 after transplantation at enrollment
* With acute or chronic GVHD
* Daily prednisone dose ≥ 0.5 mg/kg (or equivalent dose of another glucocorticoid) at enrollment.
* Negative polymerase chain reaction (PCR) for CMV at enrollment
* Provided informed consent

Exclusion Criteria:

* Seronegative for CMV
* Positive PCR for CMV at enrollment
* Patient has previously had CMV reactivation under letermovir.
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged ≥ 20 years with diagnosed GH deficiency (caused by pituitary tumor, trauma, other pituitary disease)
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use human leukocyte antigen (HLA) mismatched donors. Ultimately, a HLA mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of these patients and truly enter the era of "everyone has a donor".

This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use human leukocyte antigen (HLA) mismatched donors. Ultimately, a HLA mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of these patients and truly enter the era of "everyone has a donor".

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation with no available related human leukocyte antigen (HLA) identical sibling donors;
* No available donor with HLA high-resolution typing ≥ 9/10 or those who have difficulty finding donors due to urgent medical conditions;
* No suitable HLA matching haploidentical donor available;
* There is a suitable donor with mismatched HLA typing;
* The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.

Exclusion Criteria:

* Patients with severe liver and kidney function (alanine aminotransferase\>2.5 times the upper limit of normal, blood creatinine\>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III/IV heart function, ejection fraction\<50%, severe obstructive or restrictive ventilation dysfunction);
* Merge active infections;
* Eastern Cooperative Oncology Group (ECOG) score ≥ 2 points;
* Secondary tumors with merged activity;
* Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;
* Combine other allo HSCT contraindications.
Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.

The primary objective is to evaluate the effect of loading boluses when dose incresaing treatment with SC fentanyl in patients with cancer. The primary endpoint of this study is to prove the non-inferiority of fentanyl plasma concentrations 12 hours after dose augmentation compared to 48 hours after dose augmentation within each patient.

Patients will be treated with additional loading boluses and plasma-PK samples will be obtained.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years;
* Able to understand the written information and able to give informed consent.
* Current or planned treatment with SC fentanyl for cancer-related pain

Exclusion Criteria:

* Pregnancy or/ and breastfeeding
* Other ways of using fentanyl (sublingual, nasal spray and oromucosal)
* Liver function CPS B or C
* The use of strong CYP3A4 inhibitors of inducers \[9\]
* Presence of somnolence, respiratory depression or CTCAE grade 2 adverse events.
Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia

The goal of this study is to test the effectiveness of two experimental training programs aimed at improving face processing in developmental prosopagnosia (perception training, memory training) in comparison to an active control. The investigators will use a longitudinal design and randomize developmental prosopagnosics to three parallel arms: active control, perception training and memory training.

The investigators propose a longitudinal design with three parallel arms: active control, perception training and memory training. To maximize power, developmental prosopagnosics (DPs) in the active control group will be subsequently be offered training. Pre-training/control assessments will be performed and within 2 weeks, DPs will be randomized to one of the three training conditions. Next, all DPs will complete 6-weeks of their assigned intervention. The research assistant will provide coaching at least once per week. DPs will be assessed within two weeks of training completion and after a 12-week no-contact period. For those in the active control group, the no-contact period will serve to wash out any placebo effect and Assessment 3 will be used as their new baseline. These DPs will then be randomized to perception or memory training. Assessments will then be given to these DPs within a week after intervention completion and after a 12 weeks no-contact period.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-90
* Have lifelong histories of face recognition difficulties that impact everyday life (i.e., not associated with some event such as a stroke, seizure, etc)
* Score \> 2 standard deviations below the mean on the famous faces test and Cambridge Face Memory Test. This is in line with our previous studies and others in the literature.

Exclusion Criteria:

* History of a significant neurological disorder including hydrocephalus, stroke, moderate to severe traumatic brain injury (TBI), severe neuromuscular diseases, or severe hypoxia due to cardiac arrest.
* Participants with a history of mild TBI or simple concussion will not be excluded as long as it was \> 6 months ago and as long as they have not had repeated concussions (\>5).
* Participants will be excluded if they have impairments that interfere with cognitive performance, such as uncorrected hearing or vision, lack of English proficiency, musculoskeletal or other issues.
* Additionally, participants will be excluded if they have psychiatric disorders, such as schizophrenia, major depressive disorder, bipolar disorder, chronic intractable obsessive-compulsive disorder, or agoraphobia.
* Participants with a diagnosis of ADHD will be included as long as their medication has been consistent for the past 6 months.
* Participants who are currently dependent on alcohol or other substances will be excluded, as this may negatively impact cognitive performance.
* Participants who currently are, or within the last 6 months, participating in a behavioral or pharmacological intervention will be excluded.
Comparing Ketamine and Fentanyl in Pediatric Tonsillectomy: Pain Control and Emergence Delirium Outcomes (KVFPT)

This study is designed to compare the effectiveness of two medications, ketamine and fentanyl, in managing pain and preventing delirium in children aged 3 to 8 years who are undergoing tonsillectomy and adenoidectomy surgery. The study aims to determine which medication is better at reducing pain and preventing delirium after surgery, and which one results in faster recovery times and fewer side effects. Children participating in the study will be randomly assigned to receive either ketamine or fentanyl during their surgery. The study will measure pain levels, recovery times, and any side effects experienced by the children. The results of this study will help doctors and anesthesiologists make better decisions about which medication to use for pain management in children undergoing tonsillectomy and adenoidectomy.


Eligibility Criteria:
Inclusion Criteria:

* Children aged 3 to 8 years
* Scheduled for tonsillectomy and adenoidectomy
* American Society of Anesthesiologists (ASA) Physical Status I-III

Exclusion Criteria:

* American Society of Anesthesiologists' Physical Status ≥4
* Known hypersensitivity or allergy to any of the study medications (acetaminophen, ketamine, fentanyl)
* Receiving chronic opioid analgesic therapy prior to surgery
* Renal disease
* Hepatic disease
* Obesity (body mass index greater than 99th percentile for age)
Caring for the Whole Person

The goal of this study is to identify outcomes associated with Behavioral Health Integration (BHI) that matter to patients, to compare changes in outcome over time to measure the impact of different BHI models on different patients, and to create and maintain an Integration Learning Collaborative.

Twelve safety net clinics have been selected to be a part of this study. The clinics vary on a BHI continuum level, which includes minimal collaboration, basic collaboration at a distance, basic collaboration on site, close collaboration (partially integrated) and close collaboration (fully integrated).

Twelve-thousand patients will be randomly selected from the 12 clinics to be invited to participate in the study. Patients who elect to participate will complete a survey at baseline to collect patient-reported outcomes and again twelve months later.

The Oregon All Providers All Claims (APAC) database will be accessed to analyze financial data regarding the patients at baseline and 12 months.

The hypothesis is that the degree of clinic BHI will predict patient outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Age \>= 18
* Received care at a safety net care clinic in Oregon

Exclusion Criteria:

-
Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy

To apply an existing diagnostic imaging test (saline infusion sonohysterography by Hysteroscopic) to characterize the "filling defect" of a previous cervical cesarean delivery scar in the nonpregnant uterus


Eligibility Criteria:
Inclusion Criteria:

cesarean section diverticula patients in our hospital from 2016 to Dec 2018.The diagnosis was confirmed on the basis of medical history (at least one C-section), clinical symptoms (post¬menstrual spotting, no significant change of cycle before and after C-section),transvaginal ultrasonography (TVU), and mag¬netic resonance imaging (MRI) findings

Exclusion Criteria:

1) irregular menstrual cycle before cesar¬ean section; 2) previous placement of an intrauterine contracep¬tive device; and 3) presence of another organic uterine pathology responsible for abnormal uterine bleeding examined by hysteroscopy, such as endome-trial hyperplasia, endometrial polyps, malignancy, or submucosal myomas
Inspiratory Muscle Training in Sarcoidosis

Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea and quality of life in patients with sarcoidosis. However, no study investigated the effects of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with sarcoidosis were investigated.

Patients were diagnosed with sarcoidosis according to the criteria of the latest American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome measurement was respiratory muscle strength, secondary outcomes were, exercise capacity quality of life, fatigue and depression.

Eligibility Criteria:
Inclusion Criteria:

* Clinically stable
* Under standard medication
* Stage I and IV
* No change in medications over three months

Exclusion Criteria:

* Cognitive disorders
* Current corticosteroid use
* Having co-morbidity to prevent performing IMT
* Acute infection
* Orthopedic and neurological problems
Fatigue Management Programs for People With MS

This is a multi-site randomized clinical trial comparing 3 modes of delivering the Managing Fatigue course for reducing fatigue in individuals with multiple sclerosis (MS). The primary hypothesis is that the teleconference and internet versions of the course will be noninferior to the one-on-one, in person version in terms of the primary outcome of fatigue and secondary outcome of quality of life.

Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS). MS fatigue can impact all aspects of quality of life, including physical, mental, and social function. MS fatigue is a profound barrier to participating in meaningful activities, such as employment and hobbies. Currently, the FDA has not approved medications for MS fatigue in the United States (US). However, there are empirically tested, non-pharmacological strategies that can support people with MS in reducing the impact of fatigue. Thus, the aim of the study is to compare 3 modes of delivering the Managing Fatigue course-2 telerehabilitation formats (teleconference and internet) and 1-to-1, in-person format (traditional mode of clinical service delivery)-upon outcomes important to people with MS, i.e., fatigue and its impact on physical, mental, and social function. The intervention arms will focus on reducing fatigue as a strategy to directly improve physical, mental and social functioning.

Eligibility Criteria:
Inclusion Criteria:

* Self-report diagnosis of MS
* Age ≥ 18 years
* Fatigue Severity Scale score ≥ 4
* Ability to speak English

Exclusion Criteria:

* Individual must be capable of providing consent (Assessed with questionnaire)
* Unable to access the internet or unable to travel to in-person sessions
Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning

The goal of this observational study is to apply the CNN-based DL method to extract the three-dimensional spatial information of IMRT dose distribution to predict the occurrence probability of serious radiotherapy and chemotherapy induced oral mucositis(SRCOM), and compare with a model based on dosimetry, NTCP or doseomics to improve the prediction accuracy of SRCOM, thus guiding the clinical planning design, reducing the occurrence probability of OM, and may have the potential value of preventing serious complications and improving the quality of life in patients with nasopharyngeal carcinoma.


Eligibility Criteria:
Inclusion Criteria:

* Initial diagnosis, pathological histological diagnosis, the pathological type is non-keratotic carcinoma (according to the WHO pathological classification).
* Initial intensity-modulated radiotherapy (Intensity modulated radiation therapy, IMRT).
* No previous radiotherapy was received.

Exclusion Criteria:

* Patients with recurrent nasopharyngeal carcinoma.
* Radiotherapy plan cannot be obtained.
* Previous history of malignancy; previous radiotherapy.
* The primary lesion and cervical metastatic lesions have received surgical treatment (except for diagnostic treatment).
Measurement of Renal Functional Reserve

Single arm physiological study to measure renal functional reserve as a biomarker of kidney function and health

The investigators will measure glomerular filtration rate using urinary clearance of cold iothalamate before and after an oral protein load in patients with chronic kidney disease and healthy volunteers.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18
2. Estimated GFR \>30 mL/min/1.73m2

Exclusion Criteria:

1. Allergy to iothalamate, shellfish or iodine
2. Use of metformin or amiodarone
3. Inability to maintain a stable regimen of medications which affect GFR for \> one week prior to participation (e.g. non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers)
4. Use of medications which directly affect elimination of creatinine (e.g. cimetidine and trimethoprim)
5. Acute exacerbation of asthma or chronic obstructive pulmonary disease within 3 months requiring hospitalization or oral steroid therapy
6. Inadequate intravenous access
7. Severe anemia (Hct \<21%)
8. Acute kidney injury (rise in creatinine to ≥1.5 times the previous baseline or by ≥ 0.3 mg/dL on most recent labs prior to enrollment)
9. History of contrast-induced nephropathy
10. Hyperthyroidism
11. Pheochromocytoma
12. Sickle cell disease
13. Urinary retention or incontinence
14. Status post organ transplant
15. Pregnancy or active breast feeding
16. Cognitive impairment with inability to give consent
17. Institutionalized status
Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury

This project aims to evaluate the physiological effects of Midodrine administration during orthostatic challenge in those with high level spinal cord injury. Midodrine has been shown to improve orthostatic symptoms in those with spinal cord injury but the physiological mechanisms influenced have not been identified. The investigators will examine key physiological components influencing orthostatic tolerance. The investigators will do this, by measuring the baroreflex, and brain blood flow autoregulation (the ability to maintain brain blood flow) before during and after the sit-up test. Two sit-up tests will occur; one before Midodrine administration, and one after administration of a 10mg dose of Midodrine.


Eligibility Criteria:
Inclusion Criteria:

* To be included in the study, participants must have sustained a traumatic spinal cord injury within the ages of 18-49 years.
* Also, participants must have an injury level above the 6th thoracic vertebrae and be a non-smoker for a minimum of one year.

Exclusion Criteria:

* Any participants with a history of cardiovascular disease, pulmonary disease or diabetes mellitus will not be eligible.
* Also, participants will not be eligible to take part in study if they experiences acute distress, or are taking medications known to influence cardiovascular function.
* Patient will be not eligible for the study if he/she has known adverse reaction to Midodrine.